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Malignant glioma is characterised by extensive neovascularisation, principally influenced by vascular endothelial growth factor (VEGF).
ZD6474 is a potent inhibitor of VEGF-R2 tyrosine kinase activity, but with additional inhibitory effects on other growth factors. In this
study, we have investigated the effects of ZD6474 with regard to tumour growth, neovascularisation, proliferation and apoptosis in
the intracerebral rat glioma model, BT4C. ZD6474 (50 and 100mgkg
 1) was given as a daily oral gavage. Animals were killed on day
19 and tumour volume was measured. Sections were stained for factor VIII, Ki-67 and for apoptosis. The ability of ZD6474 to inhibit
cell growth directly was examined in vitro, using the glioma cell line BT4C and the transformed rat brain endothelial cell line RBE4. Cell
growth was analysed with fluorometric microculture cytotoxicity assay to quantify the cytotoxic effects. ZD6474 significantly
decreased tumour volume compared to controls. Microvascular density increased after treatment with ZD6474, and tumour cell
proliferation index was reduced. There was also an increase in tumour cell apoptosis. In vitro, the growth of both cell lines was
significantly reduced. The results reported justify further experimental investigations concerning the effects of ZD6474 in malignant
glioma alone or in combination with other modalities.
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Despite extensive treatment efforts, the prognosis for patients
suffering from malignant glioma is poor. The search for new
treatment modalities as well as improving the efficacy of
conventional chemotherapy and radiotherapy is therefore of
utmost importance. Malignant glioma is morphologically char-
acterised by extensive pathological neovascularisation, and micro-
vascular density (MVD) is a negative prognostic marker in both
low-grade and high-grade glioma (Leon et al, 1996; Abdulrauf et al,
1998). The neovascularisation is controlled by several different
growth regulatory factors of which vascular endothelial growth
factor (VEGF) is one of the most important (Yamada et al, 1997).
Today there are five members in the VEGF family, named A–E. All
members signal through three specific receptor tyrosine kinases.
VEGFR-1 and -2 are selectively expressed on endothelial cells and
VEGFR-3 mostly on lymphatic endothelium, but also on tumour
blood vessels (Aprelikova et al, 1992; Dvorak, 2002). Vascular
endothelial growth factor-A is recognised as the single most
important angiogenesis factor with effects on endothelial cell
proliferation, protease expression and migration (Machein and
Plate, 2000; Ferrara et al, 2003). Other growth factors are also of
obvious importance, including epidermal growth factor (EGF).
Epidermal growth factor and its receptor EGFR contribute to a
number of processes important for cancer development and
progression, including cell proliferation, apoptosis, angiogenesis
and metastatic spread (Ciardiello and Tortora, 2001). Epidermal
growth factor receptor is rarely present in normal glial cells, but is
expressed in human gliomas. The overexpression of EGFR mRNA,
caused by amplification of the erbB-1 gene, has been observed in
approximately 40–50% of human glioblastomas (Dunn et al,
2000). A truncated and constitutively activated form of EGFR,
EGFRvIII, is also frequently seen in glioma and is able to increase
VEGF expression in glioma cells (Feldkamp et al, 1999). ZD6474, a
low molecular weight receptor tyrosine kinase inhibitor (Henne-
quin et al, 2002), inhibits the VEGFR-2 tyrosine kinase with
additional effects on VEGFR-3 and EGFR (Wedge et al, 2002;
Ciardiello et al, 2003). In this study, we evaluated the effects of
ZD6474 on tumour growth in the intracerebral BT4C glioma
model.
MATERIAL AND METHODS
Animal model
The previously characterised syngenic intracerebral BT4C rat
glioma model was used for the in vivo experiments in this study
(Bergenheim et al, 1994; Johansson et al, 2000) (Figure 1). BT4C
rat glioma cells growing in log phase were suspended in Dulbecco’s
modification of Eagle’s MEM (DMEM) (Gibco, Paisley, Scotland)
supplied with 5% BD IX rat serum to a concentration of 20000
cells in 5ml. Inbred BD IX rats were anaesthetised with a 1:1
mixture of Hypnorm
s (fluanisone 10mgml
 1 and fentanyl citrate
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s0.315mgml
 1) and Dormicum
s (midazolam 5mgml
 1)
0.5ml(100g)
 1 administered as a single i.p. injection. Xylocain
s
10mgml
 1 was used for local anaesthesia in the skin of the scalp
before incision. With a 22G microsyringe (Unimetrics, Shorewood,
IL, USA) fitted to the micromanipulator of a stereotactic frame,
5ml of the cell suspension was implanted 3.5mm to the right of
bregma at a depth of 4.5mm (males) and 3.5mm (females) into the
right caudate nucleus under stereotactic conditions. Special care
was taken to prevent cellular reflux through the insertion canal and
the burr hole in the skull was covered with bone wax. During the
implantation procedure, cells were kept on ice and viability was
monitored by intermittent tryphan blue staining. After implanta-
tion animals were housed in a controlled environment with 12h
light/dark cycles and provided with food and water ad libitum.
Animals were supervised by an experienced animal keeper who
continuously evaluated their overall clinical condition.
Regarding animal welfare, consideration was taken not to
expose the animals to unmotivated suffering. The experiments
were carried out in strict accordance with the UKCCCR guidelines
(Workman et al, 1998). The experiment was approved by the local
ethics committee for animal research in accordance with the
Swedish Animal Welfare Act 1988:534 as last amended by SFS
2002:550, which are adopted in consequence of EC Directive 86/
609/EEC (see www.sweden.gov.se/content/1/c6/02/58/44/
51574064.pdf).
For this experiment, 21 animals were used and randomised into
three groups with seven animals in each group. The doses chosen
is based on published data where it is reported that ZD6474
15–100mgkgday
 1 given once daily p.o. to rats for up to 5 weeks
was well tolerated, with only small effects on body weight and no
adverse effects on clinical condition (Wedge et al, 2002). There are
no published data on experiments made in intracerebral rat
models and in this experiment we chose the doses 50 and
100mgkg
 1. These dose levels are within the range recommended
by the manufacturers. The control group received 1ml vehicle, 1%
Tween-80 (Merck-Schuchardt, Hohenbrunn, Germany) and the
other two groups were treated with ZD6474 50 and 100mgkg
 1,
respectively. ZD6474 and vehicle were given as a daily oral gavage
with disposable animal feeding needles with silicon tip (Scanbur
BK AB, Sollentuna, Sweden), starting day 6 after tumour
implantation. Animals were weighed twice a week and killed by
decapitation on day 19, before they showed neurological
symptoms. Blood samples were collected for analysis. The brains
were carefully dissected out, placed in phosphate-buffered
formalin over night and thereafter fixed in 70% ethanol until
paraffin embedded. The total treatment time for the control group
and the group receiving ZD6474 50mgkg
 1 was 13 days. Owing to
poor tolerability in the group that received ZD6474 100mgkg
 1,
the administration of ZD6474 was ended 1 day earlier. The total
treatment time for this group was therefore 12 days. Two animals
from the group receiving 100mgkg
 1 died before the rest of the
animals were killed, one at day 18 and one at day 19.
ZD6474
ZD6474 was kindly provided from Astra Zeneca, Alderly Park, UK.
For details and chemical structure, see Hennequin et al (2002). For
in vivo experiments, ZD6474 was dissolved according to the
manufacturer’s instructions in 1% Tween-80 (Merck-Schuchardt,
Hohenbrunn, Germany) to a concentration of 20mgml
 1.T o
obtain a uniform suspension, an equal volume of glass beads were
added to the mixture and the suspension was then milled over
night at room temperature and used within 1 week. For in vitro
studies, ZD6474 was dissolved in 100% DMSO (Sigma, Stockholm,
Sweden) to a concentration of 10mM. The stock solution was then
diluted in cell culture media to achieve different working
concentrations.
Tumour volume
Tumours were sectioned and stained with haematoxylin–eosin.
Tumour volume was then measured using a computerised image
analysis system. The system used consists of a stereomicroscope
(Stemi 2000-C, Carl Zeiss, Jena, Germany) with a high-resolution
digital camera (AxioCam, Carl Zeiss, Oberkochen, Germany)
under control of KS400 3.0 software (Carl Zeiss, Hallbergmoos,
Germany) in a PC computer. Images were analysed using KS400
software. Tumour height and width were measured at largest
coronar section. Tumour volume was calculated using the formula
for the ellipsoid (r1 r2 r3 p 4/3), where the radius in the
sagittal plane was approximated to be the same as the coronal
radius (Bergenheim et al, 1994).
Histological analysis of tumours
Ki-67 staining and proliferation index Proliferation index was
assessed after immunohistochemical staining for Ki-67 (Scholzen
and Gerdes, 2000). Sections chosen for immunohistochemical
staining were immersed in citrate buffer (pH 6.0) and irradiated in
microwave oven for four cycles of 5min. Endogenous peroxidase
was blocked with 10% H2O2 in methanol for 15min, followed by
blocking with normal horse serum for 20min. As primary
antibody, a monoclonal anti-rat Ki-67, at 1:25 (MIB-5, clone
M7248, DAKO A/S, Glostrup, Denmark) was incubated for 1h at
371C. After washing in PBS, sections were incubated with
biotinylated secondary horse anti-mouse antibody for 30min.
Enzyme conjugate was subsequently added for 30min. Staining
reaction was developed in 3,30-diaminobenzidine (DAB) (Sigma,
Stockholm, Sweden) and mounted using gelatine–glycerol. Cells
were manually counted in a standard light microscope (Axiophot,
Carl Zeiss, Oberkochen, Germany) and at least 600 nuclei per
tumour section were counted. Proliferation index was calculated as
the fraction of Ki-67-positive nuclei.
Apoptosis To visualise apoptosis, the Roche in situ cell death
detection kit, based on the TUNEL technique (Roche Diagnostics
Scandinavia AB, Bromma, Sweden), was used. Formalin-fixed,
paraffin-embedded tissue sections were treated with proteinase K
for 15min at 371C and blocked for endogenous peroxidase with 3%
H2O2 in methanol for 10min. Sections were then incubated for
Figure 1 An intracerebral BT4C tumour in the right hemisphere from an
animal in the control group, stained with haematoxylin–eosin. Scale bar,
2mm.
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s60min at 371C in TUNEL reaction mixture, followed by a 30min
incubation with converter-POD (peroxidase). Finally, the staining
reaction was developed in DAB (Sigma, Stockholm, Sweden) and
sections were mounted using gelatine–glycerol. Cells were
manually counted in standard light microscope (Axiophot, Carl
Zeiss, Oberkochen, Germany) avoiding necrotic tumour areas. At
least 600 nuclei per tumour section were counted. Apoptosis index
was calculated as the fraction of positive stained nuclei.
Factor VIII staining and MVD Vessels in the BT4C brain
tumours were immunohistochemically stained for factor VIII
and quantified manually using a method originally presented by
Weidner (1993). Sections chosen for immunohistochemical stain-
ing were permeabilised in 0.1% protease at 371C for 10min. After
blocking with normal goat sera, sections were incubated for 1h at
room temperature with a primary polyclonal rabbit anti-human
factor VIII antibody (DAKO A/S, Glostrup, Denmark) diluted
1:400. After washing in PBS, sections were incubated with
biotinylated secondary goat anti-rabbit antibody diluted 1:200.
Endogenous peroxidase was blocked with 10% H2O2 in methanol
for 15min. Enzyme conjugate was then added for 30min. The
staining reaction was developed in DAB (Sigma, Stockholm,
Sweden) and mounted using gelatine–glycerol. Assessment of
MVD was performed by manual counting in selected areas with the
highest vascular density (hot spots). Each tumour was scanned at
low magnification and four hot spots were chosen. All stained
objects (blood vessels with and without visible lumina) within
a  200 high-power field were counted using a standard light
microscope (Axiophot, Carl Zeiss, Oberkochen, Germany). Each
hot spot was counted twice and the arithmetical mean in each
section was used to calculate the mean MVD for each tumour,
which was used for further statistical analysis. Microvascular
density was expressed as number of vessels/ 200 high-power field
(Johansson et al, 1999).
In vitro experiments
The nitrosourea induced rat glioma cell line BT4C, kindly provided
by professor R Bjerkvig (Bergen, Norway), and the immortalised
rat brain endothelial cell line RBE4 (Regina et al, 1998), kindly
provided by Dr PO Couraud (Neurotech SA, Evry, France), were
used for in vitro studies. For BT4C assays, cells were grown in
cultures as monolayer in DMEM (Gibco, Paisley, Scotland),
supplemented with 5% fetal calf serum. Cells were harvested and
plated in a volume of 100ml at 500cellswell
 1 in microtitre plates.
ZD6474 (0–15mM) was then added to the media. RBE4 cells were
grown on calf-skin collagen-coated (Sigma, Stockholm, Sweden)
surfaces and maintained in Ham’s F10 (Gibco, Paisley, Scotland),
supplemented with 5% fetal calf serum. Cells were harvested and
plated in a volume of 100ml at 1000 cells well
 1 in microtitre plates.
ZD6474 (0–10mM) was then added to the media. Cells were
cultured until cell growth was exponential before ZD6474 was
added to the media. Plates were incubated at 371C for 6 days, and
the medium was changed after 3 days. To quantify the cytotoxic
effects of ZD6474, fluoroscein diacetate (FDA) was used in a
fluorometric microculture cytotoxicity assay (FMCA) (Larsson
et al, 1992). Cells were washed with PBS. PBS (100ml) containing
10mgl
 1 FDA was added to each well and plates were incubated in
371 for 50min, followed by fluorescence determination using 485
and 538nm for excitation and emission, respectively.
Statistics
Values are expressed as median and range. Groups were compared
using the Mann–Whitney U-test. For curve estimation, quadratic
regression was used. For this purpose, the software SPSS 11.0 for
Windows was used.
RESULTS
Inhibition of tumour growth
In the BT4C rat model, oral administration of ZD6474 50mgkg
 1
once daily for 13 days significantly decreased tumour volume from
53mm
3 (range 17–82) to 18mm
3 (range 16–33) when compared
to controls (Po0. 05) (Figure 2). The higher dose, ZD6474
100mgkg
 1 did not provide additional growth inhibitory effect,
where tumour volume was 19mm
3 (range 7–29) (Po0.05
compared to controls), with reservation for the fact that the
treatment time here was 1 day less.
Histopathological analysis of tumours
Treatment with ZD6474 50mgkg
 1 reduced the Ki-67 labelling
index significantly. The proliferation index in the control group
was 0.22 (range 0.15–0.28) compared to 0.14 (range 0.04–0.20)
(Po0.05) and 0.15 (range 0.06–0.19) (P¼NS, compared to
controls) in the group treated with ZD6474 50mgkg
 1 and
100mgkg
 1, respectively (Figure 3). The apoptotic index was
increased in the treated groups, with a value in the control group
of 0.01 (range 0.01–0.02) compared to 0.03 (range 0.01–0.05) in
the group treated with ZD6474 50mgkg
 1 (Po0.05), and 0.02
(range 0.01–0.03) (Po0.05 compared to controls), in the group
treated with ZD6474 100mgkg
 1 (Figure 4). The MVD increased
from 94 (range 79–117) to 111 (range 104–126) vessels per high-
power field (Po0.05) in animals treated with ZD6474 50mgkg
 1
compared to controls (Figure 5). In the group treated with ZD6474
100mgkg
 1, the MVD was 112 (range 80–122) vessels per high-
power field (P¼NS compared to controls).
Tolerability
In BD IX rats, once-daily oral administration of ZD6474
50mgkg
 1 for 13 days appeared well tolerated with no visible
clinical signs. ZD6474 100mgkg
 1 for 12 days made animals
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Figure 2 Treatment with ZD6474 50mgkg
 1 resulted in significant
inhibition of tumour growth from 53 (range 17–82) mm
3 to 18 (range
16–33) mm
3 compared with tumours in the control group (P¼0.032).
Treatment with ZD6474 100mgkg
 1 resulted in tumour volume 19 (range
7–29) mm
3 (P¼0.028 compared to controls). Two cases were excluded
due to ‘no tumour take’.
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slethargic and they lost significant weight (Figure 6). These animals
developed diarrhoea (in some cases blood stained), and autopsy
showed marked gastric stocking, signalling delayed gastric
emptying. Haematological toxicity was not observed in the
experiment. In the group receiving ZD6474 100mgkg
 1, the
haematocrit and the haemoglobin level were slightly elevated, most
likely due to dehydration. In all animals, leucocyte and trombocyte
counts were unaffected.
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Figure 3 Proliferation index was measured by immunohistochemical
staining for Ki-67. Treatment with ZD6474 resulted in reduced prolifera-
tion index from 0.22 (range 0.15–0.28) in the control group to 0.14 (range
0.04–0.2) (P¼0.046) and 0.15 (range 0.06–0.19) (P¼0.1 compared to
controls) in the group treated with ZD6474 50mgkg
 1 and 100mgkg
 1,
respectively.
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Figure 4 Apoptosis index increased in treated groups. In the control
group, apoptosis index was 0.01 (range 0.01–0.02). The group treated
with ZD6474 50mgkg
 1 had an apoptosis index at 0.03 (range 0.01–0.05)
(P¼0.022), and in the group treated with 100mgkg
 1, the apoptosis index
was 0.02 (range 0.01–0.03) (P¼0.022 compared to controls).
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Figure 5 Assessment of mean vessel count was performed after
immunohistochemical staining for factor VIII. Treatment with ZD6474
50mgkg
 1 resulted in increased mean vessel count from 94 (range 79–
117) to 111 (range 104–126) vessels per high-power field (P¼0.032). The
higher dose ZD6474 100mgkg
 1 resulted in a mean vessel count of 112
(range 80–122) vessels per high-power field (P¼0.36 compared to
controls).
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Figure 6 Curves of relative weight among the different groups over
time. There was no significant difference in weight between animals in the
control group compared to the low-dose group. Animals in the group
receiving ZD6474 100mgkg
 1 lost significantly in weight. As reported in
Material and Methods, two animals in the high-dose group died before the
experiment was ended (TS¼treatment start, Sacrif¼sacrifice).
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sIn vitro results
The ability of ZD6474 to inhibit cell growth directly was examined
in vitro. ZD6474 significantly and dose dependently inhibited the
growth of both BT4C and RBE4. IC50 values for inhibition of BT4C
was 2.4mM (Figure 7), and for RBE4 2.3mM (Figure 8).
DISCUSSION
In this study, we have demonstrated that the VEGFR tyrosine
kinase inhibitor ZD6474 significantly inhibits the growth of an
intracerebral rat glioma. This finding is novel and, at least to our
knowledge, it is the first time growth inhibition of an orthotopic
tumour has been reported after ZD6474 treatment. Increased
apoptosis and decreased proliferation of tumour cells in treated
animals was a finding consistent with the observed growth
inhibition in ZD6474-treated animals. In vitro, decreased growth
of tumour cells as well as of rat brain endothelial cells was
observed, which further validates the in vivo effects.
Previously, it has been shown that ZD6474 inhibits VEGF
signalling and tumour growth in a panel of subcutaneous
experimental mouse tumours of different origin (Wedge et al,
2002). Growth reductions of 70–100% after ZD6474 50mgkg
 1
treatment were reported after 14–28 days of treatment. In our
syngenic rat glioma model, growth was significantly inhibited and
a tumour volume reduction of 66% was observed after 13 days
of treatment with ZD6474 50mgkg
 1. The growth reduction
observed in our orthotopic glioma model is therefore in
accordance with previous reports in other tumour models.
However, it must be emphasised that dose levels are not easily
translated between different species, and to our knowledge there
are no other reports on ZD6474 treatment in rat tumour models.
The treatment effects in our intracerebral model also suggest that
ZD6474 crosses the blood–tumour barrier and reaches target cells
in clinically relevant concentrations. Recently, it has been shown
that ZD6474 also has a significant activity in subcutaneous CNS
tumour mouse xenografts (Rich et al, 2003). Another preliminary
report indicates that ZD6474 is inhibiting tumour growth in a
mouse model of brain metastasis (Leenders et al, 2003). These
observations together with the present findings suggest that
ZD6474 may be an interesting agent for further investigation in
experimental and clinical neuro-oncology.
In the present study, increased apoptosis and decreased
proliferation of tumour cells are distinct findings after ZD6474
treatment. The experience from other experimental antiangiogenic
treatments is somewhat different. The fragment inhibitors
angiostatin and endostatin are both considered to be mainly
angiogenesis inhibitors without effects on proliferation of tumour
cells (Sim, 1998). It is known that treatment with these
angiogenesis inhibitors results in a characteristic pattern with
increased tumour cell apoptosis and unaffected tumour cell
proliferation (O’Reilly et al, 1996, 1997). The observation that
ZD6474 also decreases tumour cell proliferation suggests that the
inhibition of tumour growth is a result of more than inhibition of
angiogenesis alone. This hypothesis is supported by our in vitro
data where growth of rat brain endothelial cells and tumour cells
both were inhibited at similar drug concentrations. Increased
apoptosis after exposure to ZD6474 in vitro has been reported for
different human cell lines (Ciardiello et al, 2003). However, in a
human lung cancer xenograft (Calu-6), Wedge et al (2002) did not
observe any change in apoptotic frequency after ZD6474
treatment. In their study, a marked increase in tumour necrosis
was reported, suggesting that the antiangiogenic effects are more
prominent in this model compared to ours. The literature on the
effects of ZD6474 on cell kinetics is so far limited and to our
knowledge our study is the first to report an increase in tumour
cell apoptosis in vivo after ZD6474 treatment.
Proliferation of rat brain endothelial cells was dose-dependently
decreased after ZD6474 treatment in vitro in our study. This has
earlier been reported for human umbilical vein endothelial cells
(HUVEC) (Wedge et al, 2002) and the effects of ZD6474 on
endothelial cells are so far undisputed. However, in our study,
RBE4 cells appear to be more resistant to ZD6474 treatment with
an IC50 more than 30-fold higher than for VEGF-stimulated
HUVEC cells, as reported by Wedge et al, 2002. The explanation
for this difference may be that the endothelial cells in the present
study were grown in serum-containing media and not stimulated
by VEGF alone. Another explanation may be that brain-derived
endothelial cells are more resistant to ZD6474 treatment compared
to HUVEC cells derived from human umbilical cord.
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Figure 7 Dose-dependent inhibition of ZD6474 on growth of BT4C
tumour cells measured by FMCA with an IC50 value of 2.4mM.
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Figure 8 Dose-dependent inhibition of ZD6474 on growth of RBE4
cells measured by FMCA with an IC50 value of 2.3mM.
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sThe effects of ZD6474 on rat brain endothelial cells in vitro
could not be translated to a decrease in MVD in vivo in the present
study. Instead, we observed a slight increase in MVD after
treatment with ZD6474 in the BT4C rat glioma model. This result
was somewhat unsuspected since it may be assumed that
successful antiangiogenic treatment reduces the number of tumour
blood vessels. Moreover, vessel density in intradermally trans-
planted A549 human lung cancer xenografts decreased after
ZD6474 treatment (Wedge et al, 2002). In a recent report, acute
changes in tumour perfusion and permeability were observed
in vivo, after treatment with ZD6474, using dynamic contrast-
enhanced MRI (Checkley et al, 2003). Together with the in vitro
data on rat brain endothelial cells and previous reports, it appears
obvious that ZD6474 has the ability to reduce endothelial cell
growth in vivo. The lack of correlation of treatment effect to a
decrease in MVD in the present study may be discussed in several
ways. From a biological point of view, vascularisation differs
widely between tumour types and models. Microvascular density
is also a time-dependent measure and the impact of MVD as a
surrogate marker for antiangiogenic therapy response may there-
fore be discussed. In a review by Hlatky et al (2002), MVD as an
indicator for antiangiogenic treatment efficacy is questioned . It is
stated that MVD may fluctuate during antiangiogenic treatment
and it may be assumed that an effective antiangiogenic treatment
initially may decrease vessel density and later during the course
of treatment a stable state or even an increase in MVD may be
predicted as tumour cells drop out. Effects on the vascular
component are not independent from effects on the tumour cell
compartment and MVD may mainly reflect the ratio of the
vascular and tumour cell components. From a methodological
point of view, the assessment of MVD is difficult and differences
in methodological approaches may also reflect the discrepancy
between the present study and the previous report by Wedge et al
(2002). Therefore, the observed MVD increase in this study does
not rule out the possibility that the tumour growth inhibitory effect
seen is at least partly due to antiangiogenic effects.
The importance of growth factor stimulation in the progression
of malignant glioma is unambiguous. Among angiogenesis factors,
VEGF is commonly believed to be the most important positive
regulator of angiogenesis in malignant glioma (Machein and Plate,
2000; Mentlein and Held-Feindt, 2003). Hypoxic tumour cells
express VEGF and thereby stimulate tumour angiogenesis, one of
the hallmarks of high-grade glioma (Plate et al, 1992). In the BT4C
rat glioma, VEGF is strongly expressed in the invasive tumour
border (Lindgren et al, 1997). Epidermal growth factor receptor
and its main ligands EGF and transforming growth factor alpha
(TGFa) are commonly overexpressed in malignant glioma (Dunn
et al, 2000). The rationale to target the VEGF and EGF axis
therefore seems obvious in malignant glioma. ZD6474 is designed
as an inhibitor of VEGFR-2, but has recently been demonstrated to
display additional inhibitory effects on EGFR (Wedge et al, 2002;
Ciardiello et al, 2003). Our in vitro data show that the inhibitory
effects of ZD6474 on tumour cells did not differ from the effects on
endothelial cells in vitro, and that proliferation of tumour cells in
vivo was decreased. This might suggest that the BT4C tumour
growth inhibition at least partly involves direct antiproliferative
effects, possibly through EGFR inhibition. Further analysis of the
expression of growth factors and their receptors from the tumour
is required to establish the precise inhibitory mechanisms in this
specific tumour model.
The use of tyrosine kinase inhibitors in the clinical setting has so
far displayed beneficial effects in a subpopulation of patients with
solid tumours. Imatinib (STI571), a receptor tyrosine kinase
inhibitor with effects on the bcr-abl tyrosine kinase, platelet-
derived growth factor receptor (PDGFR) and c-KIT is now
standard treatment in patients with chronic myeloid leukaemia
and the rare gastrointestinal stromal tumours (GIST) (Druker et al,
2001; Demetri et al, 2002). The EGFR tyrosine kinase inhibitor
gefitinib (ZD1839) displays activity in several tumours and
significant responses and survival benefit in previously treated
lung cancer patients are reported (Johnson, 2003). Several other
receptor tyrosine kinase inhibitors are under development and
in early clinical testing (Bonomi, 2003). However, so far no major
contribution has been made from receptor tyrosine kinase
inhibitors, besides imatinib for the rare GIST patients, in the
treatment of solid tumours. One possible explanation is that the
plethora of growth factors active in cancer makes the tumour
growth unaffected when only one of the signalling pathways is
blocked. The possibility to block transduction of two different
pathways stimulating different cell compartments makes ZD6474
interesting for further evaluation in malignant glioma.
To summarise, ZD6474 exerts significant antitumour effects in
an intracerebral glioma model with effects on both endothelial and
tumour cells. Thus, treatment with ZD6474 could be a novel
approach for simultaneous inhibition of both the endothelial cell
and the tumour cell components of malignant glioma. The
promising experimental results merit ZD6474 for further evalua-
tion in the treatment of malignant glioma.
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